Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database

Zhou, Jialun; Dore, Gregory J.; Zhang, Fujie; Lim, Poh Lian; Chen, Yi Ming A.

doi:10.1111/j.1440-1746.2007.05062.x

Cited by 79 publications

(68 citation statements)

References 24 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ALT activity was significantly higher among HIV/HBV co-infected participants compared to HIV monoinfected ones. This is in agreement with findings resulting from other investigations in Cameroon and worldwide in which high level of ALT was reported (Zoufaly et al, 2012;Zhou et al, 2007). The ALT is found in serum and in various bodily tissues, but high level in the serum is most commonly associated with the liver damage (e.g.…”

Section: Discussionsupporting

confidence: 82%

Human immunodeficiency virus and hepatitis B virus (HIV/HBV) co-infection in people living with HIV/AIDs identified in Yaound Central Hospital, Cameroon: Seroprevalence and impact on the disease progression

Marceline¹,

Cyriaque²,

Marlene³

et al. 2017

J. AIDS HIV Res.

View full text Add to dashboard Cite

Co-infection with HIV and hepatitis B virus (HBV) has become an important factor of co-morbidity and mortality. The aim of this study was to determine the seroprevalence of HIV/HBV co-infection and its effect on the disease progression in people living with HIV/AIDS identified in Yaoundé Central Hospital. Blood samples from 75 HIV positive patients were collected in Yaoundé Central Hospital from November 2015 to February 2016, for the determination of hepatitis B virus surface antigen (HBsAg) using immunoassays. Cluster of differentiation 4 (CD4) T-cells count and biochemical markers of liver function were also collected and analyzed. The socio-demographic data were also collected. The effect sizes were confirmed using G*Power version 3.1.9.2 software. The data were entered and analyzed using the SPSS Version 22.1 software. The statistical tests performed were x2, and Pearson correlation, with significant difference at the threshold p ≤ 0.05. Hepatitis B virus surface antigen (HBsAg) was identified in 12 patients out of 75 HIV-positive patients, for a HIV/HBV co-infection prevalence of 16%. The co-infection rate was higher in women 9 (12%) than in men 3 (4%). Among HIV infected patients, a negative and significant correlation was observed between CD4 count and ALT activity, and between the concentration of conjugated bilirubin and the activity of alkaline phosphatase (ALP) p≤ 0.05. The prevalence of HIV/HBV co-infection is higher among HIV positive patients in the Yaoundé Central Hospital. HIV associated with HBV plays a role in the disease progression. Consequently, it is important that a national management programme is in place in the country to monitor the incidence and morbidity rates of these affections.

show abstract

Section: Discussionsupporting

confidence: 82%

Human immunodeficiency virus and hepatitis B virus (HIV/HBV) co-infection in people living with HIV/AIDs identified in Yaound Central Hospital, Cameroon: Seroprevalence and impact on the disease progression

Marceline¹,

Cyriaque²,

Marlene³

et al. 2017

J. AIDS HIV Res.

View full text Add to dashboard Cite

show abstract

“…It is generally recognized among injecting drug users in HBV highly endemic areas, such as South East Asia [69]. In high-income countries, new HCV epidemics are reported among young white adults living in rural areas in the United States abusing opioids intravenously and among promiscuous homosexual men in Western Europe, North America, and Australia.…”

Section: Hepatitis C Coinfectionmentioning

confidence: 99%

Emerging Challenges in Managing Hepatitis B in HIV Patients

et al. 2015

View full text Add to dashboard Cite

Roughly 10 % of HIV-positive individuals worldwide have concomitant chronic hepatitis B virus (HBV) infection, with large differences between geographical regions and/or risk groups. Hepatitis B is a preventable infection with vaccines. However, it cannot be eradicated once acquired, resembling HIV and in contrast with HCV. In developed countries, hepatitis B exhibits particular features in the HIV population. First, HBV infection is less frequently misdiagnosed than in the general population. Second, nucleos(t)ide analogs active against HBV are widely used as part of antiretroviral combinations and are taken by most HIV patients. Lastly, as the HIV population ages given the success of antiretroviral therapy, non-AIDS co-morbidities are becoming a major cause of disease, for which specific drugs are required, increasing the risk of interactions and hepatotoxicity. Furthermore, concern on HBV reactivation is rising as immunosuppressive drug therapies are increasingly been used for cancers and other non-malignant conditions. In this scenario, new challenges are emerging in the management of hepatitis B in HIV-positive individuals. Among them, major interest is focused on failures to suppress HBV replication, HBV breakthroughs and reactivations, the meaning of isolated anti-HBc, screening for liver cancer, and the complexity arising when hepatitis viruses C and/or D are additionally present. This review will focus on these challenges and the major advances in HBV coinfection in HIV.

show abstract

“…The patient should be treated with pegylated interferon alpha and ribavirin, as indicated for chronic hepatitis C. [56] Sustained virological responses are similar to reponses in those who are monoinfected. [57][58][59] In individuals with chronic hepatitis C genotype 2 and 3, if the chronic hepatitis B requires treatment, then pegylated interferon alpha could be continued for 1 year or NUC therapy considered. There is a potential risk of HBV reactivation during treatment or after HCV clearance, which should be treated with NUCs.…”

Section: Hbv/hcv Co-infected Patientsmentioning

confidence: 99%